Joshua Hernandez Santos
Research Subjects
Joshua Hernandez Santos has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Chia-Her Lin
Department of Chemistry, National Tsing Hua University, Hsinchu 300044, Taiwan
3 shared publications - Emelda Asoy Ongo
Department of Science and Technology—Central Office, General Santos Avenue, Upper Bicutan, Taguig City 1631, Philippines
3 shared publications - Hannah Jean Victoriano
Department of Science and Technology, Industrial Technology Development Institute, General Santos Avenue, Upper Bicutan, Taguig City 1631, Philippines
3 shared publications - Hung-En Liu
Department of Chemistry, National Taiwan Normal University, No. 162, Section 1, Heping E Rd, Da’an District, Taipei City 10610, Taiwan
3 shared publications - Mary Sepulveda
Department of Science and Technology, Industrial Technology Development Institute, General Santos Avenue, Upper Bicutan, Taguig City 1631, Philippines
3 shared publications - Rikkamae Zinca Marie L. Walde
Department of Science and Technology, Industrial Technology Development Institute, General Santos Avenue, Upper Bicutan, Taguig City 1631, Philippines
3 shared publications
Latest Publications
- Open Access
- 28 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 309
Tailoring Syringic Acid–Trimesic Acid Mixed-Linker MIL-100(Fe): Evaluation of Drug-Loading Capacity, Bioavailability, and Toxicity
Background/Objectives: The use of the drug delivery system is notable for the systemic improvement of low orally bioavailable compounds, such as the bioactive phenolic acid, syringic acid. Innovative techniques are employed to enhance the performance of certain drug delivery systems. In connection with our previously reported journal with the use of MIL-100(Fe) as a drug carrier for syringic acid, this study utilized a mixed-linker synthesis of syringic acid and trimesic acid and characterized the properties in comparison with the unmodified MIL-100(Fe) through a solid solution approach. Methods: Modified MIL-100(Fe) was synthesized by substituting different molar concentrations of syringic acid for trimesic acid through de novo synthesis. Simple impregnation of syringic acid was carried out at 12, 24, 36, and 48 h and at 1:1 and 1:2 molar ratios of MIL-100(Fe) to syringic acid. Characterization was performed via PXRD, FTIR, BET, SEM, and DLS. In vivo studies included acute oral toxicity testing (OECD 425) and bioavailability assessment in Sprague Dawley rats. Results: The optimized amount of syringic acid to be substituted for trimesic acid is 0.10 mmol, as confirmed by the value of the PXRD. Optimized drug loading of 66.85 ± 0.004% was achieved using a 1:2 ratio of syringic acid to MIL-100(Fe)-10% over 36 h. Structural modifications were confirmed via FTIR, specifically through shifts at 1239.2 cm−1, while TGA demonstrated thermal stability up to approximately 350 °C. Morphological analysis by SEM showed octahedral particles (210.70 ± 1.23 nm), and a decrease in BET surface area post-loading verified successful encapsulation. While in vitro release was media-dependent, toxicity studies at 2000 mg/kg showed no adverse effects; notably, SGOT and SGPT levels decreased, though BUN and creatinine levels rose. Compared to pure oral syringic acid, the SYA@MIL-100(Fe)-10% formulation demonstrated a 5.09-fold increase in relative bioavailability. Furthermore, it outperformed intraperitoneal administration of the drug by 1.65-fold. Conclusions: Modification of MIL-100(Fe) by incorporating syringic acid into the framework as a substituted organic linker indicates that SYA@MIL-100(Fe)-10% is a safe and effective delivery system for syringic acid, enhancing oral bioavailability. To the best of our knowledge, this is the first study to investigate the mixed-linker synthesis of MIL-100(Fe) by utilizing syringic acid as a structural co-ligand, rather than solely as an encapsulated guest. While MIL-100(Fe) has been extensively employed as a carrier for various therapeutics, this research uniquely integrates the active agent into the framework lattice itself to modulate porosity and loading capacity, subsequently evaluating its systemic performance in an in vivo model.
- 28 February 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (3) , 309
Open AccessTailoring Syringic Acid–Trimesic Acid Mixed-Linker MIL-100(Fe): Evaluation of Drug-Loading Capacity, Bioavailability, and Toxicity
Background/Objectives: The use of the drug delivery system is notable for the systemic improvement of low orally bioavailable compounds, such as the bioactive phenolic acid, syringic acid. Innovative techniques are employed to enhance the performance of certain drug delivery systems. In connection with our previously reported journal with the use of MIL-100(Fe) as a drug carrier for syringic acid, this study utilized a mixed-linker synthesis of syringic acid and trimesic acid and characterized the properties in comparison with the unmodified MIL-100(Fe) through a solid solution approach. Methods: Modified MIL-100(Fe) was synthesized by substituting different molar concentrations of syringic acid for trimesic acid through de novo synthesis. Simple impregnation of syringic acid was carried out at 12, 24, 36, and 48 h and at 1:1 and 1:2 molar ratios of MIL-100(Fe) to syringic acid. Characterization was performed via PXRD, FTIR, BET, SEM, and DLS. In vivo studies included acute oral toxicity testing (OECD 425) and bioavailability assessment in Sprague Dawley rats. Results: The optimized amount of syringic acid to be substituted for trimesic acid is 0.10 mmol, as confirmed by the value of the PXRD. Optimized drug loading of 66.85 ± 0.004% was achieved using a 1:2 ratio of syringic acid to MIL-100(Fe)-10% over 36 h. Structural modifications were confirmed via FTIR, specifically through shifts at 1239.2 cm−1, while TGA demonstrated thermal stability up to approximately 350 °C. Morphological analysis by SEM showed octahedral particles (210.70 ± 1.23 nm), and a decrease in BET surface area post-loading verified successful encapsulation. While in vitro release was media-dependent, toxicity studies at 2000 mg/kg showed no adverse effects; notably, SGOT and SGPT levels decreased, though BUN and creatinine levels rose. Compared to pure oral syringic acid, the SYA@MIL-100(Fe)-10% formulation demonstrated a 5.09-fold increase in relative bioavailability. Furthermore, it outperformed intraperitoneal administration of the drug by 1.65-fold. Conclusions: Modification of MIL-100(Fe) by incorporating syringic acid into the framework as a substituted organic linker indicates that SYA@MIL-100(Fe)-10% is a safe and effective delivery system for syringic acid, enhancing oral bioavailability. To the best of our knowledge, this is the first study to investigate the mixed-linker synthesis of MIL-100(Fe) by utilizing syringic acid as a structural co-ligand, rather than solely as an encapsulated guest. While MIL-100(Fe) has been extensively employed as a carrier for various therapeutics, this research uniquely integrates the active agent into the framework lattice itself to modulate porosity and loading capacity, subsequently evaluating its systemic performance in an in vivo model.
- Open Access
- 1 October 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (10) , 1282
MIL-100(Fe)-Enabled Oral Delivery of Syringic Acid with Enhanced Pharmacokinetics
Background/Objectives: Plant-derived bioactive compounds like syringic acid, a phenolic acid from the shikimic acid pathway, have shown potential against chronic diseases, including diabetes, cardiovascular disorders, cancer, and cerebral ischemia. However, its poor water solubility and rapid systemic elimination result in low oral bioavailability, limiting therapeutic potential. This study aimed to enhance its oral bioavailability using MIL-100(Fe), a metal–organic framework (MOF) known for high surface area and drug-loading capacity. Methods: MIL-100(Fe) was synthesized using an optimized method and loaded with syringic acid through impregnation at 12, 24, 36, and 48 h. Characterization included PXRD, FTIR, BET, SEM, and DLS. Acute oral toxicity was evaluated following OECD 423 guidelines, and bioavailability was assessed in Sprague Dawley rats. Results: The 1:2 MIL-100(Fe) to syringic acid ratio achieved the highest drug loading at 64.42 ± 0.03% (12 h). PXRD and FTIR confirmed successful loading (notably at 1239.2 cm−1), and TGA indicated thermal stability at ~350 °C. SEM revealed octahedral particles with an average size of 270.67 ± 2.60 nm. BET showed reduced surface area post-loading. In vitro drug release exhibited media-dependent profiles. Toxicity tests indicated no adverse effects at 2000 mg/kg. Oral administration of SYA@MIL-100(Fe) resulted in a 10.997-fold increase in relative bioavailability versus oral syringic acid and a 12.82-fold increase compared to intraperitoneal administration. Conclusions: MIL-100(Fe) is a safe and effective oral carrier for syringic acid, significantly enhancing its bioavailability. This platform shows strong potential for delivering phenolic compounds in pharmaceutical applications.
- 1 October 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (10) , 1282
Open AccessMIL-100(Fe)-Enabled Oral Delivery of Syringic Acid with Enhanced Pharmacokinetics
Background/Objectives: Plant-derived bioactive compounds like syringic acid, a phenolic acid from the shikimic acid pathway, have shown potential against chronic diseases, including diabetes, cardiovascular disorders, cancer, and cerebral ischemia. However, its poor water solubility and rapid systemic elimination result in low oral bioavailability, limiting therapeutic potential. This study aimed to enhance its oral bioavailability using MIL-100(Fe), a metal–organic framework (MOF) known for high surface area and drug-loading capacity. Methods: MIL-100(Fe) was synthesized using an optimized method and loaded with syringic acid through impregnation at 12, 24, 36, and 48 h. Characterization included PXRD, FTIR, BET, SEM, and DLS. Acute oral toxicity was evaluated following OECD 423 guidelines, and bioavailability was assessed in Sprague Dawley rats. Results: The 1:2 MIL-100(Fe) to syringic acid ratio achieved the highest drug loading at 64.42 ± 0.03% (12 h). PXRD and FTIR confirmed successful loading (notably at 1239.2 cm−1), and TGA indicated thermal stability at ~350 °C. SEM revealed octahedral particles with an average size of 270.67 ± 2.60 nm. BET showed reduced surface area post-loading. In vitro drug release exhibited media-dependent profiles. Toxicity tests indicated no adverse effects at 2000 mg/kg. Oral administration of SYA@MIL-100(Fe) resulted in a 10.997-fold increase in relative bioavailability versus oral syringic acid and a 12.82-fold increase compared to intraperitoneal administration. Conclusions: MIL-100(Fe) is a safe and effective oral carrier for syringic acid, significantly enhancing its bioavailability. This platform shows strong potential for delivering phenolic compounds in pharmaceutical applications.
- Open Access
- 24 July 2025
- Published by MDPI AG in Preprints.org
MIL-100(Fe)-Enabled Oral Delivery of Syringic Acid with Enhanced Pharmacokinetics
Background/Objectives: Plant-derived bioactive compounds like syringic acid, a phenolic acid from the shikimic acid pathway, have shown potential against chronic diseases including diabetes, cardiovascular disorders, cancer, and cerebral ischemia. However, its poor water solubility and rapid systemic elimination result in low bioavailability, limiting therapeutic potential. This study aimed to enhance its bioavailability using MIL-100(Fe), a metal-organic framework (MOF) known for high surface area and drug-loading capacity. Methods: MIL-100(Fe) was synthesized using an optimized method and loaded with syringic acid through impregnation at 12, 24, 36, and 48 hours. Characterization included PXRD, FTIR, BET, SEM, and DLS. Acute oral toxicity was evaluated following OECD 425 guidelines, and bioavailability was assessed in Sprague Dawley rats. Results: The 1:2 syringic acid to MIL-100(Fe) ratio achieved the highest drug loading at 64.42 ± 0.03% (12 h). PXRD and FTIR confirmed successful loading (notably at 1242 cm⁻¹), and TGA indicated thermal stability at ~450 °C. SEM revealed octahedral particles with an average size of 270.67 ± 2.60 nm. BET showed reduced surface area post-loading. In vitro drug release exhibited media-dependent profiles. Toxicity tests indicated no adverse effects at 2000 mg/kg. Oral administration of SYA@MIL-100(Fe) resulted in a 10.997-fold increase in relative bioavailability versus oral syringic acid and 12.82-fold over intraperitoneal administration. Conclusions: MIL-100(Fe) is a safe and effective oral carrier for syringic acid, significantly enhancing its bioavailability. This platform shows strong potential for delivering phenolic compounds in pharmaceutical applications.
- 24 July 2025
- Published by MDPI AG in Preprints.org
Open AccessMIL-100(Fe)-Enabled Oral Delivery of Syringic Acid with Enhanced Pharmacokinetics
Background/Objectives: Plant-derived bioactive compounds like syringic acid, a phenolic acid from the shikimic acid pathway, have shown potential against chronic diseases including diabetes, cardiovascular disorders, cancer, and cerebral ischemia. However, its poor water solubility and rapid systemic elimination result in low bioavailability, limiting therapeutic potential. This study aimed to enhance its bioavailability using MIL-100(Fe), a metal-organic framework (MOF) known for high surface area and drug-loading capacity. Methods: MIL-100(Fe) was synthesized using an optimized method and loaded with syringic acid through impregnation at 12, 24, 36, and 48 hours. Characterization included PXRD, FTIR, BET, SEM, and DLS. Acute oral toxicity was evaluated following OECD 425 guidelines, and bioavailability was assessed in Sprague Dawley rats. Results: The 1:2 syringic acid to MIL-100(Fe) ratio achieved the highest drug loading at 64.42 ± 0.03% (12 h). PXRD and FTIR confirmed successful loading (notably at 1242 cm⁻¹), and TGA indicated thermal stability at ~450 °C. SEM revealed octahedral particles with an average size of 270.67 ± 2.60 nm. BET showed reduced surface area post-loading. In vitro drug release exhibited media-dependent profiles. Toxicity tests indicated no adverse effects at 2000 mg/kg. Oral administration of SYA@MIL-100(Fe) resulted in a 10.997-fold increase in relative bioavailability versus oral syringic acid and 12.82-fold over intraperitoneal administration. Conclusions: MIL-100(Fe) is a safe and effective oral carrier for syringic acid, significantly enhancing its bioavailability. This platform shows strong potential for delivering phenolic compounds in pharmaceutical applications.
- Open Access
- 6 December 2023
- Published by Qeios Ltd
Review of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"
The paper is very good, multiple pathophysiology of A.D. is being addressed or explored but with some issues: * Isoeugenol crosses the BBB - How does the authors address or correlate the presence of other factors which makes or prevent drugs from...
- 6 December 2023
- Published by Qeios Ltd
Open AccessReview of: "Targeting Alzheimer's disease hallmarks with the Nrf2 activator Isoeugenol"
The paper is very good, multiple pathophysiology of A.D. is being addressed or explored but with some issues: * Isoeugenol crosses the BBB - How does the authors address or correlate the presence of other factors which makes or prevent drugs from...
- Open Access
- 14 September 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (38) , 24382-24396
Computational and Experimental Assessments of Magnolol as a Neuroprotective Agent and Utilization of UiO-66(Zr) as Its Drug Delivery System
- 14 September 2021
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 6 (38) , 24382-24396
Open AccessComputational and Experimental Assessments of Magnolol as a Neuroprotective Agent and Utilization of UiO-66(Zr) as Its Drug Delivery System
- Open Access
- 9 May 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (5) , 437
Enhanced Oral Bioavailability of the Pharmacologically Active Lignin Magnolol via Zr-Based Metal Organic Framework Impregnation
Bioavailability plays an important role in drug activity in the human body, as certain drug amounts should be present to elicit activity. However, low bioavailability of drugs leads to negligible use for human benefit. In this study, the diversely active neolignan, magnolol, was impregnated onto a Zr-based organometallic framework [Uio-66(Zr)] to increase its low bioavailability (4–5%) and to test its potential acute oral toxicity. Synthesis of Uio-66(Zr) was done through the solvothermal method while simple impregnation at different time points was used to incorporate magnolol. The loading capacity of Uio-66(Zr) at 36 h was found to be significantly higher at 72.16 ± 2.15% magnolol than in other incubation time. Based on the OECD 425 (limit test), toxicity was not observed at 2000 mg kg−1 dose of mag@Uio-66(Zr) in female Sprague Dawley rats. The area under the curve (AUC) at 0–720 min of mag@Uio-66(Zr) was significantly higher than the AUC of free magnolol. Moreover, relative bioavailability increased almost two-folds using Uio-66(Zr). Unconjugated magnolol was found in the liver, kidney, and brain of rats in all treatment groups. Collectively, Uio-66(Zr) provided a higher magnolol bioavailability when used as drug carrier. Thus, utilization of Uio-66(Zr) as drug carrier is of importance for maximal use for poorly soluble and lowly bioavailable drugs.
- 9 May 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (5) , 437
Open AccessEnhanced Oral Bioavailability of the Pharmacologically Active Lignin Magnolol via Zr-Based Metal Organic Framework Impregnation
Bioavailability plays an important role in drug activity in the human body, as certain drug amounts should be present to elicit activity. However, low bioavailability of drugs leads to negligible use for human benefit. In this study, the diversely active neolignan, magnolol, was impregnated onto a Zr-based organometallic framework [Uio-66(Zr)] to increase its low bioavailability (4–5%) and to test its potential acute oral toxicity. Synthesis of Uio-66(Zr) was done through the solvothermal method while simple impregnation at different time points was used to incorporate magnolol. The loading capacity of Uio-66(Zr) at 36 h was found to be significantly higher at 72.16 ± 2.15% magnolol than in other incubation time. Based on the OECD 425 (limit test), toxicity was not observed at 2000 mg kg−1 dose of mag@Uio-66(Zr) in female Sprague Dawley rats. The area under the curve (AUC) at 0–720 min of mag@Uio-66(Zr) was significantly higher than the AUC of free magnolol. Moreover, relative bioavailability increased almost two-folds using Uio-66(Zr). Unconjugated magnolol was found in the liver, kidney, and brain of rats in all treatment groups. Collectively, Uio-66(Zr) provided a higher magnolol bioavailability when used as drug carrier. Thus, utilization of Uio-66(Zr) as drug carrier is of importance for maximal use for poorly soluble and lowly bioavailable drugs.
- Open Access
- 1 July 2018
- Published by Wolters Kluwer Health in Philippine Journal of Health Research and Development
- Vol. 22 (3) , 45-55
Characterization and Stability Study of Reduced L-glutathione-loaded Niosomes
Background: Glutathione is a major antioxidant in the body that serves as a substrate for conjugation reactions and regulates cell proliferation. Low levels of glutathione have been linked to cancer, liver problems and other chronic diseases. Studies have shown that oral supplementation is not effective in increasing the glutathione level in the body. Objectives: The purpose of the study was to prepare a niosomal formulation of glutathione and to characterize the niosomal formulation. Furthermore, the study compared the effect of the charge inducer in the formulation. Methodology: The method was divided to the preparation, characterization and stability study of the niosomal formulation. The niosomal formulation was produced by thin film hydration with varying Span 60 (Sorbitan monostearate) and cholesterol ratios. Niosomal formulation with highest entrapment efficiency was further characterized for mean particle size, surface morphology, and in vitro drug release. Results and Discussion: Formulation A entrapped 98.21% of the glutathione. Addition of charge inducer increased its entrapment efficiency to 98.91%. Furthermore, both niosomal formulations released glutathione at pH 7.4 in 1.0M phosphate buffer saline (PBS). The mean vesicular size obtained was 1,242.97 + 40.52nm. Differential Scanning Calorimetry revealed compatibility between glutathione and its excipients. Both formulations do not cause cytotoxicity in human dermal fibroblast. The stability study also revealed that it was stable at 5°C and 40°C for 3 months. Conclusion: Results of this study suggested the potential use of niosomes in the targeted delivery of glutathione. This is the first report on the use of niosomal preparations through thin film hydration technique in the delivery of reduced L-glutathione.
- 1 July 2018
- Published by Wolters Kluwer Health in Philippine Journal of Health Research and Development
- Vol. 22 (3) , 45-55
Open AccessCharacterization and Stability Study of Reduced L-glutathione-loaded Niosomes
Background: Glutathione is a major antioxidant in the body that serves as a substrate for conjugation reactions and regulates cell proliferation. Low levels of glutathione have been linked to cancer, liver problems and other chronic diseases. Studies have shown that oral supplementation is not effective in increasing the glutathione level in the body. Objectives: The purpose of the study was to prepare a niosomal formulation of glutathione and to characterize the niosomal formulation. Furthermore, the study compared the effect of the charge inducer in the formulation. Methodology: The method was divided to the preparation, characterization and stability study of the niosomal formulation. The niosomal formulation was produced by thin film hydration with varying Span 60 (Sorbitan monostearate) and cholesterol ratios. Niosomal formulation with highest entrapment efficiency was further characterized for mean particle size, surface morphology, and in vitro drug release. Results and Discussion: Formulation A entrapped 98.21% of the glutathione. Addition of charge inducer increased its entrapment efficiency to 98.91%. Furthermore, both niosomal formulations released glutathione at pH 7.4 in 1.0M phosphate buffer saline (PBS). The mean vesicular size obtained was 1,242.97 + 40.52nm. Differential Scanning Calorimetry revealed compatibility between glutathione and its excipients. Both formulations do not cause cytotoxicity in human dermal fibroblast. The stability study also revealed that it was stable at 5°C and 40°C for 3 months. Conclusion: Results of this study suggested the potential use of niosomes in the targeted delivery of glutathione. This is the first report on the use of niosomal preparations through thin film hydration technique in the delivery of reduced L-glutathione.